Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 18/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4112235 | 0.95 | CHRM3 (0.71) | CHRM3CHRM2CHRM1 | |
| Trifluoroacetic Acid SCHEMBL4094083 | 0.90 | CHRM3 (0.71) | CHRM3CHRM2CHRM1 | |
| Trifluoroacetic Acid SCHEMBL4100245 | 0.89 | CHRM3 (0.69) | CHRM3CHRM2CHRM1 | |
| Trifluoroacetic Acid SCHEMBL4106109 | 0.89 | CHRM3 (0.68) | CHRM3CHRM2CHRM1 | |
| Trifluoroacetic Acid SCHEMBL1632566 | 0.85 | CHRM3 (0.67) | CHRM3CHRM2CHRM1 | |
| Trifluoroacetic Acid SCHEMBL4093626 | 0.85 | CHRM3 (0.66) | CHRM3CHRM2CHRM1 | |
| Trifluoroacetic Acid SCHEMBL4100580 | 0.85 | CHRM3 (0.90) | CHRM3CHRM1 | |
| Trifluoroacetic Acid SCHEMBL4109356 | 0.85 | CHRM3 (0.73) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4100719 | 0.84 | CHRM3 (0.79) | CHRM3CHRM2CHRM1 | |
| SCHEMBL4105238 | 0.84 | CHRM3 (0.74) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725236-A4 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-05-13 | — | — | EP | claimed |
| EP-1725236-A1 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-11-29 | — | — | EP | claimed |
| WO-2005087236-A1 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-09-22 | — | — | WO | claimed |
| US-20090253908-A1 | NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253908-A1 | NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRNA3 | CHRM3 1/4885CHRM2 2/4885CHRM1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.